Drug class in one race
GDF-15 drugs for Non-Small Cell Lung Cancer
2 tracked GDF-15 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the GDF-15 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
1 Phase 21 Phase 1
Head-to-head evidence: PF-06946860 vs Visugromab